Natco Pharma is planning to diversify its product portfolio in the domestic market as it aims to make up for a drop in business of some of its prominent product categories. Its oncology segment suffered in the last financial year due to pricing controls from the government, and its Hepatitis-C business continued to decline due to reduction in market size. The company is planning for new product launches in the non-oncology segment to mitigate the impact of the Hepatitis-C market decline.
Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.
